FDA approves innovative, non-invasive heart valve

November 2, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- Federal health officials have approved a first-of-a-kind artificial heart valve that can be implanted without major surgery, offering a new treatment option for patients who are too old or frail for the chest-cracking procedure currently used.

The Food and Drug Administration said late Wednesday it approved Edwards Lifesciences' Sapien heart valve, which can be threaded into place through a major artery that runs from the leg up to the heart. Cardiologists say the highly anticipated new approach will help old, sickly patients who cannot undergo the more invasive open heart surgery, which has been used to replace valves for decades.

Other companies have won approval for less-invasive heart valves before, but Edwards' implant is the first replacement for the aortic valve, the heart's main doorway.

About 300,000 U.S. patients suffer from deterioration of the valve, which forces the heart to work harder to pump blood, often leading to heart failure, blood clots and sudden death. More than half of patients diagnosed with the condition, called aortic stenosis, die within two years, according to the FDA.

Every year about 50,000 people in the U.S. undergo open-heart surgery to replace the valve, which involves sawing the breastbone in half, stopping the heart, cutting out the old valve and sewing a new one into place. Thousands of other patients are turned away, deemed too old or ill to survive the operation.

The Mayo Clinic's Dr. David Holmes said the Sapien valve is a "game changer" for those inoperable patients, many of whom are in their 80s with medical conditions like diabetes, emphysema and liver disease.

"We don't have very good therapy for them at this time - some of them receive palliative care and some receive medication," said Holmes, who is president of the American College of Cardiology. "But this is really a mechanical problem, and for mechanical problems medications don't work very well."

Edwards' transcatheter valve is threaded through the femoral artery via a small incision in the leg, and then guided up to the heart via catheter. The valve is then wedged into the aortic opening by an inflatable balloon, replacing the natural heart valve. The device is made from cow tissue and polyester supported by a steel frame.

FDA based its approval on a 365-patient study that compared outcomes for patients with the valve and those who received basic comfort care and other non-surgical treatment. After one year, 70 percent of patients with the valve were still alive, compared with only 50 percent of those who received alternatives. However, the device was associated with serious complications, including stroke and internal bleeding. Under the conditions of FDA approval, Edwards will track the medical history of all patients who receive the valve.

The device is only approved for patients who cannot undergo open-heart surgery.

About 20,000 new U.S. patients will be eligible to receive a heart valve each year based on Wednesday's approval, according to Morgan Keegan analyst Jan Wald.

The larger opportunity for the new valve is in patients who are healthy enough to undergo surgery, but are considered high-risk and could benefit from a less invasive procedure. The FDA is expected to clear the device for those patients next year, and analysts estimate that group could eventually number between 50,000 and 80,000 annually as the U.S. population ages.

Edwards is expected to charge about $30,000 for the valve, though hospital fees could bring the total cost of surgery closer to $70,000. Standard heart valve replacement costs upward of $50,000, mostly from surgical and hospitalization fees.

The approval represents a dramatic business opportunity for Irvine, Calif.-based Edwards Lifesciences Corp., which had total sales of $1.5 billion last year. Analysts estimate that sales of the Sapien valve could help double the company's revenue to $3 billion within a decade. Company shares rose $3.11, or 4.2 percent, to $77.48 in after-hours trading.

The company expects to train surgeons at 150 to 250 sites across the U.S. to implant the Sapien in the coming year.

The valve has already been approved for four years in 40 countries around the world, including most of Europe. In most of those countries Edwards already sells a next-generation version of the device.

Explore further: FDA favors innovative heart valve for the frail


Related Stories

FDA favors innovative heart valve for the frail

July 18, 2011
The first artificial heart valve designed to be implanted without major surgery appears to help patients who are too frail to undergo chest-opening surgery, according to federal health reviewers.

Heart valve replacement without opening the chest gives new option for non-operable patients

June 24, 2011
An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered at Rush University Medical Center to patients with severe aortic stenosis who are at high-risk or not suitable candidates ...

New procedure at UMC replaces pulmonary valve, avoids open-heart surgery

April 18, 2011
(PhysOrg.com) -- Veronica Smith, 26, of Sierra Vista was the first person in Arizona to receive a new pulmonary valve without having open-heart surgery. The procedure took place at University Medical Center.

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.